BlueTech Nexus
Technical Objective
Present five Navy-developed technologies to industry, investors, and technologists for potential commercialization partnerships and licensing. The primary featured technology is a 3D-printed microfluidic artificial muscle system that generates high biomimetic force density with acoustic stealth, designed for robotic and mechanical applications. This reverse pitch model aims to accelerate technology transfer from NPS research into the commercial market.
Core Technologies
Who Should Apply
Private sector companies, investors, and technologists interested in licensing or partnering on Navy-developed technologies, particularly those with expertise in robotics, advanced materials, microfluidics, or mechanical systems. No specific company size or clearance requirements are stated; this is an open industry engagement event.
Evaluation Criteria
- 1Commercial viability and market opportunity of proposed applications
- 2Technical fit with Navy operational needs
- 3Partnership and licensing terms
Key Dates
| Registration Deadline | 2026-09-14 |
| In-Person Reverse Pitch Event | 2026-09-22 |
Submission Mechanics
This is an in-person reverse pitch event (not a formal R&D solicitation with written proposals). Interested parties must register in advance due to limited space. Attendance at Hopkins Marine Station on September 22, 2026 at 1800 is required to receive technology briefings and participate in the after-event mixer.
BD Strategic Notes
This opportunity is best suited for commercial robotics firms, advanced manufacturing companies, and defense contractors seeking early access to disruptive Navy technologies. The focus on force density, acoustic stealth, and 3D-printable design suggests strong fit with autonomous systems, undersea robotics, and next-generation actuator markets.
Watch Out For
- Limited registration capacity — early sign-up required
- In-person attendance mandatory (no virtual option mentioned)
- This is a networking/pitch event, not a formal funding opportunity — licensing and partnership terms would be negotiated separately
- IP ownership and licensing details not disclosed in advance